Literature DB >> 16470521

Central nervous system-related permanent consequences in patients with Langerhans cell histiocytosis.

Edda Mittheisz1, Rainer Seidl, Daniela Prayer, Marion Waldenmair, Birgit Neophytou, Ulrike Pötschger, Milen Minkov, Manuel Steiner, Helmut Prosch, Martha Wnorowski, Helmut Gadner, Nicole Grois.   

Abstract

BACKGROUND: Permanent consequences in Langerhans cell histiocytosis (LCH) are irreversible late sequelae related to the disease that may severely impair the quality of life of survivors. The frequency and pattern of permanent consequences affecting the central nervous system (CNS) remains to be determined. PROCEDURE: In this single center study, 25 LCH patients observed for a median time of 10 years 3 months underwent a uniform thorough follow-up program including neuropsychological testing and electrophysiological evaluation.
RESULTS: Overall permanent consequences were seen in 9 of 25 patients. Intracranial abnormalities were the most frequent including diabetes insipidus (DI) in seven patients, anterior pituitary deficiencies in five patients, and neurodegenerative CNS disease in five patients. No patient had overt neurological symptoms upon neurological evaluation, but psychological testing revealed subtle deficits in short-term auditory memory (STAM) in 14 patients. Brain stem evoked potentials showed abnormalities in four of nine tested patients, all of these four had neurodegeneration on MRI.
CONCLUSION: Psychoneuroendocrine sequelae were found in an unexpectedly high number of patients in this single center study. Long-term follow-up focusing on such sequelae are important in LCH survivors, in order to detect early deficits, to monitor the evolution of the disease, and to provide specific support. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2007        PMID: 16470521     DOI: 10.1002/pbc.20760

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  13 in total

1.  Endocrine manifestations of Langerhans cell histiocytosis diagnosed in adults.

Authors:  M S García Gallo; M P Martínez; M S Abalovich; S Gutiérrez; M A Guitelman
Journal:  Pituitary       Date:  2010-12       Impact factor: 4.107

2.  Neurodegeneration in the course of Langerhans cell histiocytosis.

Authors:  F Spagnolo; E Leopizzi; R Cardamone; M Falautano; V Martinelli; G Comi; M A Volonté
Journal:  Neurol Sci       Date:  2011-07-09       Impact factor: 3.307

3.  Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside.

Authors:  Carl E Allen; Ricardo Flores; Ronald Rauch; Robert Dauser; Jeffrey C Murray; Diane Puccetti; David A Hsu; Paul Sondel; Maxine Hetherington; Stan Goldman; Kenneth L McClain
Journal:  Pediatr Blood Cancer       Date:  2010-03       Impact factor: 3.167

4.  Long-term MR imaging course of neurodegenerative Langerhans cell histiocytosis.

Authors:  H Prosch; N Grois; M Wnorowski; M Steiner; D Prayer
Journal:  AJNR Am J Neuroradiol       Date:  2007 Jun-Jul       Impact factor: 3.825

5.  The pituitary gland in patients with Langerhans cell histiocytosis: a clinical and radiological evaluation.

Authors:  Neslihan Kurtulmus; Meral Mert; Refik Tanakol; Sema Yarman
Journal:  Endocrine       Date:  2014-09-11       Impact factor: 3.633

Review 6.  Langerhans cell histiocytosis.

Authors:  Joan Manel Gasent Blesa; Vicente Alberola Candel; Carlos Solano Vercet; Juan Laforga Canales; Christof Semler; Maria Rosa Pérez Antolí; Carlos Rodríguez-Galindo
Journal:  Clin Transl Oncol       Date:  2008-11       Impact factor: 3.340

7.  Early Diagnosis and Monitoring of Neurodegenerative Langerhans Cell Histiocytosis.

Authors:  Elena Sieni; Carmen Barba; Marzia Mortilla; Sara Savelli; Laura Grisotto; Gianpiero Di Giacomo; Katiuscia Romano; Claudio Fonda; Annibale Biggeri; Renzo Guerrini; Maurizio Aricò
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

8.  Diffuse reduction of cerebral grey matter volumes in Erdheim-Chester disease.

Authors:  Eli L Diamond; Vaios Hatzoglou; Sneha Patel; Omar Abdel-Wahab; Raajit Rampal; David M Hyman; Andrei I Holodny; Ashish Raj
Journal:  Orphanet J Rare Dis       Date:  2016-08-02       Impact factor: 4.123

9.  Optimal therapy for adults with Langerhans cell histiocytosis bone lesions.

Authors:  Maria A Cantu; Philip J Lupo; Mrinalini Bilgi; M John Hicks; Carl E Allen; Kenneth L McClain
Journal:  PLoS One       Date:  2012-08-15       Impact factor: 3.240

10.  Association between Pituitary Langerhans Cell Histiocytosis and Papillary Thyroid Carcinoma.

Authors:  Salvatore Guarino; Deborah Maria Giusti; Antonello Rubini; Pasqualino Favoriti; Cristina Fioravanti; Filippo Maria Di Matteo; Vito D'Andrea; Enrico De Antoni; Antonio Catania
Journal:  Clin Med Insights Case Rep       Date:  2013-12-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.